SAM CHERIAN: Open Payments
NPI 1972208726 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,639 in 66 payments from 14 companies in 2025. Trend: 2023 $1,051 · 2024 $725 · 2025 $1,639
Food & beverage: $1,540Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $520 |
| AstraZeneca Pharmaceuticals LP | 9 | $207 |
| Astellas Pharma US Inc | 5 | $168 |
| Amgen Inc. | 2 | $139 |
| Teva Pharmaceuticals USA, Inc. | 1 | $135 |
| Axsome Therapeutics, Inc. | 4 | $118 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| Lilly USA, LLC | 4 | $61 |
| SHIELD THERAPEUTICS INC | 3 | $61 |
| Novo Nordisk Inc | 2 | $44 |
Products named: VRAYLAR, KRYSTEXXA, AUSTEDO XR, Auvelity, FARXIGA, CAPLYTA, Veozah, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
